^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    LY3143921

    i
    Other names: LY3143921, LY 3143921, LY-3143921
    Company:
    Eli Lilly
    Drug class:
    CDC7 kinase inhibitor
    Related drugs:
    1year
    CRUKD/17/004: A CR-UK Phase I Trial of LY3143921 (clinicaltrials.gov)
    P1, N=69, Active, not recruiting, Cancer Research UK | Trial completion date: Jul 2023 --> Feb 2027 | Trial primary completion date: Jul 2023 --> Feb 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    LY3143921
    over2years
    CRUKD/17/004: A CR-UK Phase I Trial of LY3143921 (clinicaltrials.gov)
    P1, N=69, Active, not recruiting, Cancer Research UK | Recruiting --> Active, not recruiting | N=115 --> 69 | Trial completion date: Jan 2022 --> Jul 2023 | Trial primary completion date: Jan 2022 --> Jul 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    LY3143921
    over2years
    A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors. (ASCO 2022)
    LY3143921 is well tolerated, exhibits dose-dependent increases in plasma exposure and demonstrates evidence of target inhibition. Significant monotherapy clinical activity was not observed; further analyses should investigate potential predictive response biomarkers and rational combination approaches.
    Clinical • P1 data
    |
    TP53 (Tumor protein P53) • CDC7 (Cell Division Cycle 7)
    |
    TP53 mutation
    |
    LY3143921
    3years
    A CR-UK Phase I Trial of LY3143921 (clinicaltrials.gov)
    P1, N=115, Recruiting, Cancer Research UK | N=68 --> 115
    Clinical • Enrollment change
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    LY3143921